Headache and Migraine

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.

A migraine forecasting model achieved 91% precision using app data, but the study did not test whether next-day predictions improve care.

Here's some of what is coming soon to NeurologyLive® this week.

Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.

A review of 12 studies showed that maternal migraine was linked to a higher likelihood of infant colic, and that infant colic was in turn linked to a higher risk of migraine later in childhood.

The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.

The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.

Findings from a new study showed that over 90% of counties in the United States lacked a UCNS-certified headache specialist, with access lowest in socioeconomically disadvantaged and rural areas.

Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.

The FDA has granted De Novo Authorization to Avulux's optical-filter lenses to reduce light sensitivity in patients aged 12 years or older with episodic migraine.

A narrative review highlighted the limited pediatric-specific evidence supporting headache treatment after stroke and in cerebrovascular disorders, emphasizing consideration of vascular pathophysiology, cerebral perfusion, and collateral flow when selecting therapies.

Clinician author Kevin Chang, PharmD, writes about PACAP as a distinct, druggable migraine pathway independent of CGRP, offering a promising option for patients who don't respond to current therapies.

Six FDA PDUFA decisions this fall could reshape care in Alzheimer disease, DMD, Sanfilippo syndrome, Alexander disease, and SMA, here's what clinicians need to know about the data behind each.

Cleveland Clinic experts Trishul Kapoor, MD, and Osama Kashlan, MD, discussed how advanced diagnostics, basivertebral nerve ablation, endoscopic surgery, and neuromodulation unite to ease chronic back pain.

In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a standalone diagnostic biomarker.

AbobotulinumtoxinA met its primary end point in both the E-BEOND and C-BEOND phase 3 trials, marking the first time a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine prevention.

Phase 2b PROCEED trial results and a phase 1 drug interaction study for bocunebart were presented at AHS 2026, collectively strengthening the drug's development case as a first-in-class PACAP-targeting therapy.

European regulators have expanded atogepant’s label to include acute migraine treatment, supported by phase 3 data showing significant pain freedom and sustained relief versus placebo.

A retrospective study presented at AAN 2026 suggested that short-course methylprednisolone tapers may reduce headache severity and daily headache burden in patients with acute posttraumatic headache after mild traumatic brain injury.